Company: GNMSF
Filing Date: 2025-02-12
Form Type: 20-F
Source: 0001558370-25-000846
Chunk: 38

Company: GENMAB A/S
Filing Date: 2025-02-12
Form: 20-F
Item: Item 4I
Chunk 38
---
 companies share all costs and future potential profits for HexaBody-OX40 on a 50:50 basis. A Phase I/II clinical trial of HexaBody-OX40 in solid tumors is recruiting. 
GEN1160 
GEN1160 was acquired as part of our purchase of ProfoundBio. It is a CD70-targeted ADC. CD70 is a protein expressed on both solid tumors and hematological malignancies. A Phase I/II clinical study of GEN1160 in advanced renal cell carcinoma, nasopharyngeal carcinoma and NHL is recruiting.
​GEN1107 
GEN1107 is a PTK7-targeted ADC. PTK7 is a clinically validated ADC target with broad solid tumor expression, particularly in tumor-initiating cells. A Phase I/II clinical study of GEN1107 in advanced solid tumors is recruiting.
DuoBody- FAPαxDR4 (GEN1057)
DuoBody-FAPαxDR4 is a bispecific antibody-based investigational medicine created using Genmab’s DuoBody technology platform. DuoBody-FAPαxDR4 is designed for the conditional transactivation of DR4 and thereby induction of apoptosis. A Phase I/II clinical trial of DuoBody-FAPαxDR4 in malignant solid tumors is recruiting.
​GEN1286
GEN1286 is an ADC targeting EGFR and cMet, two validated cancer targets. A Phase I/II clinical study of GEN1286 in advanced solid tumors is recruiting.
​

46

Partnered programs Incorporating Genmab’s Innovation and Technology1
​
Approved Medicines

                             Approved Product                                               Discovered and/or Developed &amp; Marketed By                        Disease Indication(s) 2      
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
DARZALEX(daratumumab)/DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)   J&amp;J (Royalties to Genmab on net global sales)                              MM                                
                                                                                                                                                            AL Amyloidosis                    
RYBREVANT(amivantamab/amivantamab-vmjw)                                      J&amp;J (Royalties to Genmab on net global sales)                              NSCLC                             
TECVAYLI (teclistamab/teclistamab-cqyv)                                      J&amp;J (Royalties to Genmab on net global sales)                              R/R MM                            
TALVEY (talquetamab/talquetamab